• Innovative Eye Science

    Your vision is our focus

    Play
    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >

News

Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes

NEW YORK--(BUSINESS WIRE)--Jun. 22, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announced that the Company will join the broad-market Russell 3000® and Russell 2000® Indexes. The newly reconstituted indexes take effect after the close on Friday, June 22, 2018. Russell US Indexes are widely used...

Read More >